Xeris Biopharma Holdings (XERS) Cash & Equivalents (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Cash & Equivalents data on file, last reported at $111.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 91.22% year-over-year to $111.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $111.8 million (up 91.22% YoY) and the FY2025 annual result came in at $111.0 million, up 55.04% from the prior year.
• Cash & Equivalents grew to $111.8 million in Q1 2026, from $111.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $122.0 million in Q4 2022 to a low of $46.1 million in Q3 2023.
• A 5-year average of $76.4 million and a median of $67.4 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 51.57% — and 2026, when it soared 91.22%.
• Tracing XERS's Cash & Equivalents over 5 years: stood at $122.0 million in 2022, then slumped by 44.7% to $67.4 million in 2023, then increased by 6.19% to $71.6 million in 2024, then surged by 55.04% to $111.0 million in 2025, then increased by 0.64% to $111.8 million in 2026.
• The last three Cash & Equivalents figures came in at $111.8 million (Q1 2026), $111.0 million (Q4 2025), and $91.6 million (Q3 2025), per Business Quant data.